Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
9/18/2024 | $112.00 → $118.00 | Buy | BofA Securities | |
8/21/2024 | $85.00 | Hold → Sell | DZ Bank | |
8/14/2024 | $80.00 → $110.00 | Hold → Buy | Stifel | |
8/14/2024 | $85.00 → $118.00 | Hold → Buy | Deutsche Bank | |
8/14/2024 | $80.00 → $120.00 | In-line → Outperform | Evercore ISI | |
8/13/2024 | $85.00 → $103.00 | Neutral → Overweight | Piper Sandler | |
8/13/2024 | $81.00 → $105.00 | Hold → Buy | TD Cowen | |
8/13/2024 | $110.00 | Neutral → Outperform | Robert W. Baird |
4 - STARBUCKS CORP (0000829224) (Issuer)
4 - STARBUCKS CORP (0000829224) (Issuer)
4 - STARBUCKS CORP (0000829224) (Issuer)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)
SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)
4 - STARBUCKS CORP (0000829224) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Below are some instances of options activity happening in the Consumer Discretionary sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume BABA CALL TRADE BULLISH 08/02/24 $79.00 $27.0K 2.4K 1.7K SBUX CALL TRADE B
Deep-pocketed investors have adopted a bullish approach towards Starbucks (NASDAQ:SBUX), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SBUX usually suggests something big is about to happen. We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Starbucks. This level of activity is out of the ordinary. The general mood among these heavyweight investors is divided, with 75% leaning bullish and 8% bearish. Among these notable options, 5 a
Starbucks's (NYSE:SBUX) short percent of float has risen 12.44% since its last report. The company recently reported that it has 25.61 million shares sold short, which is 2.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.05 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is
8-K - STARBUCKS CORP (0000829224) (Filer)
8-K - STARBUCKS CORP (0000829224) (Filer)
10-Q - PALISADE BIO, INC. (0001357459) (Filer)
BofA Securities reiterated coverage of Starbucks with a rating of Buy and set a new price target of $118.00 from $112.00 previously
DZ Bank downgraded Starbucks from Hold to Sell and set a new price target of $85.00
Stifel upgraded Starbucks from Hold to Buy and set a new price target of $110.00 from $80.00 previously
Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate patients switching from prior anti-CD20 treatment can successfully eliminate initial BRIUMVI infusion NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. Highlights from the presentation are outlined below. Michael S. Weiss, the Company's Chairman an
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 5 years of continuous treatment, with no new safety signals emerging with prolonged treatment NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced updated data presentations including new five-year data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual
– Company remains committed to its mission to become a leader in developing differentiated product candidates targeting immune, inflammatory and fibrotic diseases – Successful completion of nonclinical safety and toxicity studies and continued execution of regulatory requirements towards launch of Phase 1 human clinical study for lead program, PALI-2108 for the treatment of UC before year end Carlsbad, CA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today anno
Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:
Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-2) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity
Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
WEST PALM BEACH, Fla., Aug. 13, 2024 /PRNewswire/ -- Elliott Investment Management L.P. ("Elliott"), today released the following statement from Elliott Managing Partner Jesse Cohn and Partner Marc Steinberg regarding Starbucks Corporation (NYSE:SBUX) (the "Company" or "Starbucks") and its engagement with the Company: Elliott has become one of the largest investors in Starbucks because of our confidence in the long-term value-creation opportunity we see at one of the world's most important brands. Elliott has been engaged with Starbucks' Board over the past two months regardin
Brian Niccol will join Starbucks on September 9, 2024. Mellody Hobson will be lead independent director. Laxman Narasimhan is stepping down as ceo and as a director effective immediately. Rachel Ruggeri will serve as interim ceo. Starbucks (NASDAQ:SBUX) today announced that Brian Niccol has been appointed chairman and chief executive officer. Niccol will start in his new role on September 9, 2024. Starbucks chief financial officer, Rachel Ruggeri, will serve as interim ceo until that time. Mellody Hobson, Starbucks board chair, will become lead independent director. Niccol currently serves as Chairman and CEO of Chipotle. Since becoming CEO in 2018, Niccol has transformed Chipotle. His
Second quarter 2024 U.S. BRIUMVI net revenue of $72.6 million Raising full year 2024 U.S. BRIUMVI net revenue target to approximately $290 - $300 million Cash flow positive for second quarter 2024 Establishes $250 million credit facility to repay existing debt and to buy back up to $100 million of common stock under a share repurchase program Initiated phase 1 study in RMS patients for subcutaneous ublituximab and received FDA IND clearance to study azer-cel (allogeneic CD19 CAR-T) in patients with progressive MS Conference call to be held today, August 6, 2024, at 8:30 AM ET NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therape
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Tuesday August 6, 2024 at 8:30 AM ET to discuss results for the second quarter of 2024 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Second Quarter Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An au
Q3 Consolidated Net Revenues of $9.1 Billion, Down 1%; Up 1% in Constant Currency; Up 6% Over Q2 Q3 GAAP and Non-GAAP EPS of $0.93; Action Plans Partially Offset Continued Headwinds Q3 Active U.S. Starbucks® Rewards Membership Totals 33.8 Million, Up 7% Over Prior Year and Up 3% Over Q2 Starbucks Corporation (NASDAQ:SBUX) today reported financial results for its 13-week fiscal third quarter ended June 30, 2024. GAAP results in fiscal 2024 and fiscal 2023 include items that are excluded from non-GAAP results. Please refer to the reconciliation of GAAP measures to non-GAAP measures at the end of this release for more information. Q3 Fiscal 2024 Highlights Global comparable store sales